Ionis

News

Novartis shares have slipped after it revealed its Lp(a)-targeted drug, pelacarsen, failed to reduce cardiovascular risks in a major phase 3 trial.

News

Ionis' Zanvastro has been approved by the FDA for Alexander disease, becoming the first disease-modifying therapy for the devastating rare disease.

News

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.

News

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.